Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

VIATRIS INC

Filed by VIATRIS INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 22, 2025
Income
Not reported
Expenses
$590,000.00
Registrant
VIATRIS INC.
Filing UUID
3e7612f2-3a91-48f3-9640-bad55b8c6079
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages The Medication Affordability and Patent Integrity Act

Literal federal measure citations: S. 891, H.R. 1843, S. 1302, HR 4132, S.2027

CPT · Copyright/Patent/Trademark

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Literal federal measure citations: S 1553

TRD · Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain

FIN · Financial Institutions/Investments/Securities

Policy related to corporate governance

DEF · Defense

S.2296 National Defense Authorization Act

Literal federal measure citations: S.2296

BUD · Budget/Appropriations

HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)

Literal federal measure citations: HR 9747

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.